Deals
As the World Gets Fatter, This Pharma Giant Gets Richer
- Novo Nordisk tops total returns of big European pharma firms
- Big mergers are "something you don't do unless you have to"
Diabetes Will Strike One in Ten Adults by 2030, IDF Report
Guido Krzikowski/BloombergThis article is for subscribers only.
Late on a chilly Friday in February 2013, Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen got news that his company’s most promising new treatment, an insulin called Tresiba, had been rejected by U.S. regulators.
Soerensen spent the weekend in meetings and on conference calls crafting a response, but one idea was never on the table: a big acquisition to add new drugs and soften the impact of the Tresiba delay.